CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
B-Dim +1 moredrug
Likely dose
B-Dim 225 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00888654
NCT00888654Phase 2Completed
CompareCT.gov

Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy

Barbara Ann Karmanos Cancer Institute·interventional·Posted Apr 27, 2009·Updated Mar 19, 2018

In Brief

A Phase 2 clinical trial evaluating B-Dim and Radical Prosatectomy for Prostate Cancer. Completed, enrolled 41 participants across 2 sites.

Detailed Summary

RATIONALE: The use of diindolylmethane, a substance found in cruciferous vegetables, may slow the growth of tumor cells. PURPOSE: This phase II trial is studying how well diindolylmethane works in treating patients with stage I or stage II prostate cancer undergoing radical prostatectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 27, 2009
Enrollment StartAug 1, 2009
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 17.2 years ago

Interventions

B-Dimdrug

B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)

Radical Prosatectomyprocedure